Akebia Therapeutics (AKBA) Long-Term Deferred Tax (2018 - 2019)
Akebia Therapeutics (AKBA) reported Long-Term Deferred Tax of $109.4 million for Q4 2019, down 3.04% year-over-year from $112.8 million in Q4 2018, and down 3.04% quarter-over-quarter from $112.8 million in Q4 2018.
Akebia Therapeutics (AKBA) Long-Term Deferred Tax (2018 - 2019) Analysis & Trends
Akebia Therapeutics (AKBA) has 2 years of Long-Term Deferred Tax data on file, last reported at $109.4 million in Q4 2019.
- Long-Term Deferred Tax for Q4 2019 came in at $109.4 million, down 3.04% year-over-year; the trailing twelve-month figure through Dec 2019 was $109.4 million (down 3.04% YoY), and the FY2019 annual result was $109.4 million, down 3.04% from the prior year.
- Long-Term Deferred Tax slipped to $109.4 million in Q4 2019 per AKBA's latest filing, from $112.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $112.8 million in Q4 2018 and troughed at $109.4 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 109.35 Mn |
| Dec 31, 2018 | 112.78 Mn |